HAPSTR2 Activators
Activators of HAPSTR2 employ a variety of mechanisms to enhance its functional activity, primarily through the modulation of phosphorylation states and second messenger systems. For instance, the stimulation of adenylyl cyclase activity by certain compounds leads to a rise in intracellular cAMP levels, which in turn activates protein kinase A (PKA). The activated PKA can then phosphorylate HAPSTR2, increasing its activity. Additionally, the inhibition of phosphodiesterases plays a crucial role in maintaining elevated levels of cAMP and cGMP, further sustaining the activation of HAPSTR2 through PKA and other cGMP-dependent protein kinases. Moreover, the activation of AMP-activated protein kinase (AMPK) in response to energy stress also triggers a cascade of phosphorylation events that can culminate in the enhanced activity of HAPSTR2.
Another set of activators works by modulating protein kinase C (PKC) and adenosine A2B receptors, which are known to influence intracellular signaling cascades that can lead to the phosphorylation and subsequent activation of HAPSTR2. Certain inhibitors of tyrosine kinases can also result in altered phosphorylation patterns that favor the activation of HAPSTR2. Beyond these, phosphatase inhibitors contribute to the activation of HAPSTR2 by preventing the dephosphorylation of proteins, thereby promoting a sustained phosphorylated state that supports the active conformation of HAPSTR2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Directly stimulates adenylyl cyclase, increasing intracellular cAMP levels, which can enhance the activity of HAPSTR2 by cAMP-dependent protein kinase A (PKA) phosphorylation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, which elevates intracellular cAMP and cGMP by preventing their degradation, leading to activation of HAPSTR2 through PKA-dependent mechanisms. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
Activates AMP-activated protein kinase (AMPK), which can lead to subsequent activation of HAPSTR2 through phosphorylation during energy stress response. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Membrane-permeable cAMP analog that activates PKA; this can lead to phosphorylation and activation of HAPSTR2. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Protein kinase C (PKC) activator which may lead to phosphorylation and activation of HAPSTR2 as part of signaling cascades. | ||||||
BAY 60-6583 | 910487-58-0 | sc-503262 | 10 mg | $210.00 | ||
Agonist for adenosine A2B receptors, potentially leading to increased intracellular cAMP and subsequent activation of HAPSTR2 via PKA signaling. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Phosphodiesterase inhibitor that raises cGMP levels, which could indirectly activate HAPSTR2 through cGMP-dependent protein kinases. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Tyrosine kinase inhibitor that can lead to altered phosphorylation patterns, potentially increasing the activity of HAPSTR2. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selective inhibitor of phosphodiesterase 4, increasing cAMP levels and potentially leading to the activation of HAPSTR2 through PKA-dependent phosphorylation. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Inhibitor of phosphodiesterase 3 which increases cAMP levels, potentially resulting in the activation of HAPSTR2 via PKA signaling pathways. | ||||||